Dr. Clay Siegall’s recent interview with Inspirery reveals some excellent insights into his character. Clay Siegall is the CEO and founder of Seattle Genetics. His bitotech firm is operates out of Seattle. The firm specializes in developing therapy drugs that target specific disease types. His research and results look promising. There has been a substantial improvement in the mortality rate of patients who use his drugs.
His educational background is in zoology, and he holds a B.S. degree. He went on to receive his Ph.D in Genetics from George Washington University. The targeted therapy field of medicine is still relatively new. However, his firm is a disrupter in the industry in having developed the first antibody conjugate that was FDA-approved. Siegall also takes credit for having developed more than 20 drugs along with strategic partnerships to manufacture his drugs. These partnerships include Bayer, Pfizer, and Genetech to name several.
His company has also experienced robust growth since its inception. It is now a major player in the cancer research space, and has come a long way from its tiny startup days. As such, Seattle Genetics positions itself to continue expanding its list of drugs within a vibrant pipeline of products. The applications for, already existing, his drugs offer unlimited opportunities for potential applications. His company will continue to be a major contender well into the 21st century.
Siegall’s drive to create targeted therapy drugs comes from his belief that the old ways of treating cancer with processes like chemotherapy will become a relic of the past. Even though targeted therapies are in their initial stage, it continually becomes clearer they will become the way of the near future. Targeted drugs will likely replace harsh, older, therapies.
The world always moves forward. Thus, one can expect new thoughts, ideas, methods, and products to continually materialize. Clay Siegall is a true innovator in his field, and the world will be a better place for his energy and creativity.